Strong Support for Not Interrupting Imatinib Treatment in Advanced GIST
MedPage Today) -- Patients with advanced non-progressing gastrointestinal stromal tumors (GIST) who discontinued imatinib had more rapid progression, faster development
Menu
Menu
- 07/06/2025 03:20 9 tell-tale signs your client project is heading for chaos (and what to do next)
- 07/06/2025 03:20 Selman rebrands the Cathedral of St. John the Divine
- 07/06/2025 03:20 The Working Assembly blurs the lines for Pinky Swear’s genre-defying identity
- 07/06/2025 01:20 Why Kissinger would have been a Fortnite champ − and other foreign policy lessons from the gaming world
- 07/06/2025 01:19 Why the Musk and Trump relationship is breaking down – a psychologist explains
- 07/06/2025 01:19 ‘Godfather of AI’ now fears it’s unsafe. He has a plan to rein it in
- 06/06/2025 23:19 Trump announces U.S.-China trade talks in London next week
- 06/06/2025 23:19 Trump considers getting rid of his Tesla on heels of Elon Musk feud
- 06/06/2025 23:19 International stocks are ahead of the U.S. so far this year—how to add them to your portfolio
- 06/06/2025 21:20 Book Riot’s Deals of the Day for June 6, 2025
